AHR and asthma: Another cell surface TLRs agonist is Pam3CSK4 that acts as a synthetic TLR2 agonist and exhibits antiasthmatic effects by reducing Th2 cytokine release, AHR, IgE levels, airway inflammation, and asthmatic symptoms in animal models of asthma [67].